These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29604102)

  • 1. Systematic Review and Meta-Analysis of Real-World Studies Evaluating Rivaroxaban for Cancer-Associated Venous Thrombosis.
    Martinez BK; Sheth J; Patel N; Baker WL; Coleman CI
    Pharmacotherapy; 2018 Jun; 38(6):610-618. PubMed ID: 29604102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.
    Kohn CG; Lyman GH; Beyer-Westendorf J; Spyropoulos AC; Bunz TJ; Baker WL; Eriksson D; Meinecke AK; Coleman CI
    J Natl Compr Canc Netw; 2018 May; 16(5):491-497. PubMed ID: 29752323
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
    Kimpton M; Carrier M
    Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.
    Søgaard M; Nielsen PB; Skjøth F; Kjaeldgaard JN; Larsen TB
    Cancer Med; 2019 Mar; 8(3):1044-1053. PubMed ID: 30767432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
    Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
    Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study.
    Mantha S; Laube E; Miao Y; Sarasohn DM; Parameswaran R; Stefanik S; Brar G; Samedy P; Wills J; Harnicar S; Soff GA
    J Thromb Thrombolysis; 2017 Feb; 43(2):166-171. PubMed ID: 27696084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
    Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
    Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Khorana AA; Weitz JI
    Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Nicklaus MD; Ludwig SL; Kettle JK
    J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J; Baker WL
    Am J Med; 2019 Apr; 132(4):498-504. PubMed ID: 30582894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
    Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
    Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.
    Bott-Kitslaar DM; Saadiq RA; McBane RD; Loprinzi CL; Ashrani AA; Ransone TR; Wolfgram AA; Berentsen MM; Wysokinski WE
    Am J Med; 2016 Jun; 129(6):615-9. PubMed ID: 26797081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis.
    Mohamed MFH; ElShafei MN; Ahmed MB; Abdalla LO; Ahmed I; Elzouki AN; Danjuma MI
    Clin Appl Thromb Hemost; 2021; 27():1076029620940046. PubMed ID: 33651658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.